Bioregnum channel feed – Endpoints News

SIGN UP

Bioregnum channel feed

Who's confidently investing in biotech startups during these tense days? We've got some answers

6 days ago

Amit Munshi has more than $300M and a startup CSO out to pioneer next-gen RNA therapeutics. Once again, he’s thinking big

3 weeks ago

Ex-FDA neuro chief Billy Dunn is taking a spin through the revolving door with biopharma — and that's a problem

3 weeks ago

The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with

4 weeks ago

When is a preclinical drug worth a mother lode of cash? This top 20 list offers a few answers

5 weeks ago

Remember that record biotech IPO party in 2018? There was no ‘happily ever after’

5 weeks ago

In a surprise shift, Tony Coles taps his successor as CEO of Bain startup Cerevel

Last month

J&J goes blockbuster hunting (again) with $245M cash upfront for next-gen CAR-T

Last month

Another big Vertex challenger suffers a TKO. And that will cause some problems for the CF champ

Last month

HSBC is moving to fill a big gap left by SVB's collapse. And they've recruited some familiar faces for the leap

Last month

In a bittersweet transition, Doug Williams takes on his next big biotech challenge

Last month

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

2 months ago

Jeffrey Bluestone brings his startup haul to $400M+, joining forces with Regeneron on cell therapies

2 months ago

The venture crew at Mubadala are upping their biotech creation game, taking careful aim at a new frontier in drug development

2 months ago

A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test

3 months ago

Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

3 months ago

John Reed lands in the top R&D post at J&J in his latest Big Pharma debut

3 months ago

The top 100 venture investors in biopharma today. Who's staying at the deals table?

3 months ago

Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role

4 months ago

A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality

4 months ago

Updated: R&D turbulence at Bristol Myers now includes the end of a $650M alliance and the departure of a top research champion

4 months ago

Pioneering biotech icon George Scangos hands in his retirement papers — and this time it’s for real

4 months ago

What’s with Bristol Myers’ R&D job cuts in New Jersey? They’re not saying much

4 months ago

Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster

5 months ago

12 3 4 Next page Last page